Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
Kibe S, Yutani S, Motoyama S, Nomura T, Tanaka N, Kawahara A, Yamaguchi T, Matsueda S, Komatsu N, Miura M, Hinai Y, Hattori S, Yamada A, Kage M, Itoh K, Akagi Y, Sasada T. Kibe S, et al. Among authors: sasada t. Cancer Immunol Res. 2014 Dec;2(12):1154-62. doi: 10.1158/2326-6066.CIR-14-0035. Epub 2014 Oct 28. Cancer Immunol Res. 2014. PMID: 25351849 Clinical Trial.
Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
Kawano K, Tsuda N, Matsueda S, Sasada T, Watanabe N, Ushijima K, Yamaguchi T, Yokomine M, Itoh K, Yamada A, Kamura T. Kawano K, et al. Among authors: sasada t. Immunopharmacol Immunotoxicol. 2014 Jun;36(3):224-36. doi: 10.3109/08923973.2014.913617. Epub 2014 Apr 29. Immunopharmacol Immunotoxicol. 2014. PMID: 24773550 Clinical Trial.
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
Yamada T, Terazaki Y, Sakamoto S, Yoshiyama K, Matsueda S, Komatsu N, Waki K, Yamada A, Kawahara A, Kage M, Sugawara S, Yamashita Y, Sasada T, Takamori S, Itoh K. Yamada T, et al. Among authors: sasada t. Int J Oncol. 2015 Jan;46(1):55-62. doi: 10.3892/ijo.2014.2699. Epub 2014 Oct 7. Int J Oncol. 2015. PMID: 25310280 Clinical Trial.
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Sasada T, Hattori N, Kohno N, Itoh K. Sakamoto S, et al. Among authors: sasada t. Cancer Sci. 2015 Oct;106(10):1257-63. doi: 10.1111/cas.12757. Epub 2015 Sep 25. Cancer Sci. 2015. PMID: 26212219 Free PMC article. Clinical Trial.
Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kudo M, Noguchi M. Yutani S, et al. Among authors: sasada t. J Immunol Res. 2015;2015:473909. doi: 10.1155/2015/473909. Epub 2015 Oct 11. J Immunol Res. 2015. PMID: 26539554 Free PMC article. Clinical Trial.
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, Ohyama C, Nasu Y, Tanaka M, Moriya F, Suekane S, Matsueda S, Komatsu N, Sasada T, Yamada A, Kakuma T, Itoh K. Noguchi M, et al. Among authors: sasada t. Clin Cancer Res. 2016 Jan 1;22(1):54-60. doi: 10.1158/1078-0432.CCR-15-1265. Epub 2015 Nov 18. Clin Cancer Res. 2016. PMID: 26581246 Clinical Trial.
212 results